Horowitz L N
Philadelphia Heart Institute, Presbyterian Medical Center of Philadelphia, Pennsylvania 19104.
Am J Cardiol. 1990 Feb 20;65(8):41D-46D; discussion 68D-71D. doi: 10.1016/0002-9149(90)91416-4.
Moricizine hydrochloride has been shown to be effective in the treatment of a variety of ventricular arrhythmias. It has been evaluated for the treatment of malignant ventricular arrhythmias in several hundred patients. When assessed by noninvasive techniques, moricizine effectively suppresses spontaneous unsustained ventricular tachycardia (VT) in approximately 60% of patients. Efficacy is sustained during long-term therapy. Evaluation of moricizine therapy for sustained VT using programmed stimulation has been carefully performed in more than 100 patients. The initiation of sustained VT is suppressed in 20 to 25% of patients. Moricizine is generally well tolerated. Because of its minimal effects on left ventricular function, a common clinical problem in patients with malignant ventricular arrhythmias and relatively low potential for proarrhythmia, moricizine has a role in the treatment of malignant ventricular arrhythmias in selected patients.
盐酸莫雷西嗪已被证明对多种室性心律失常有效。它已在数百名患者中进行了治疗恶性室性心律失常的评估。通过非侵入性技术评估时，莫雷西嗪可有效抑制约60%患者的自发性非持续性室性心动过速（VT）。在长期治疗期间疗效持续。已对100多名患者仔细进行了使用程序刺激评估莫雷西嗪治疗持续性VT的研究。20%至25%的患者持续性VT的诱发得到抑制。莫雷西嗪一般耐受性良好。由于其对左心室功能影响极小，而左心室功能问题在恶性室性心律失常患者中很常见，且致心律失常潜力相对较低，因此莫雷西嗪在选定患者的恶性室性心律失常治疗中具有一定作用。
